DiaSys And Merck S.A. Expand Exclusive Two-Year Sales and Service Agreement.Business Editors WATERBURY, Conn.--(BUSINESS WIRE)--Dec. 18, 2002 DiaSys Corporation (AMEX AMEX See: American Stock Exchange :DYX DYX Dyslexia ), a global healthcare products company, today announced that it has expanded the application of its exclusive two-year sales and service agreement with Merck S.A., a subsidiary of Merck KGaA This article needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. (XETRA Xetra Deutsche Borse electronic trading platform that commenced operation in 1997. : MRCG.DE), the world renowned pharmaceutical and chemistry products producer based in Darmstadt, Germany. Under the expanded agreement, Merck S.A. will promote, sell and service DiaSys' medical equipment and consumable products in Colombia, as well as previously announced Guatemala, Honduras and Nicaragua. Since the inception of their relationship at the end of August, 2002, Merck S.A. has ordered for immediate delivery multiple DiaSys products, especially DiaSys "R/S R/S Remote Sensing R/S Rally Sport R/S Respectfully Submit R/S Report of Survey R/S Route Sheet R/S Reentry System R/S Revision Segment R/S Rationalization & Standardization R/S Regulatory or Safety (automotive requirements) " series workstations for urine sediment analysis, "FE" series workstations for analysis of parasites and ovum, and the DiaSys Parasep line of consumable products for the collection and filtration of fecal materials. Carlos Aldana, Manager of Diagnostic Products for Merck S.A., said, "The quality of DiaSys' products and service has allowed us to rapidly penetrate our markets. The "R/S" and "FE" workstations fill important technological gaps in our product line, and allow our customers to achieve a high level of procedural standardization and reproducibility." He added, "The continued cooperation with DiaSys will strengthen our position as a leading provider of laboratory products in Central and South America South America, fourth largest continent (1991 est. pop. 299,150,000), c.6,880,000 sq mi (17,819,000 sq km), the southern of the two continents of the Western Hemisphere. ." Richard Sledziona, DiaSys' Director Of Sales for South and Central America said, "The addition of Colombia to our agreement confirms that Merck S.A. is the ideal partner to secure our position in key Central and South American markets. With Merck's assistance, we will continue to strengthen and widen the supply chain of DiaSys products to these parts of the world." DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and test kits to healthcare laboratories worldwide. Headquartered in Waterbury, CT, the Company operates in Europe through its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. based in Wokingham, England and in Pacific Asia through its strategic business partner located in Guangzhou, China. "DiaSys" and "Parasep" are registered trademarks of DiaSys Corporation. The foregoing press release includes "forward looking statements" within the meaning of, and made pursuant to, the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion